Born in 1965. Chairman of the Board since 2023.

Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industries including Oasmia Pharmaceutical AB. Julian is an entrepreneur who ran his own companies for many years in several different business areas, primarily pharmaceutical development. Is an active investor and through companies also a major owner in a number of listed companies.

Number of shares *): 25,677,309
shares through Maida Vale Capital AB
TO4 warrants: 9,375,000 through Maida Vale Capital AB

Education: Economist

Other assignments: Board member of Maida Vale Capital AB and Hunterhex AB.

Independent in relation to the company and its management but not to major shareholders. 

Born in 1969. Board member since 2021.

Anders has more than 25 years of experience within international finance and business development in the pharmaceutical– and medical device industries. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture  capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB,  Selego AB. 

Number of shares *): 23,284

Education: BSc in Business Administration and Economics at Uppsala University  

Ongoing assignments: Chairman of the board of Maida Vale Capital AB, Terranet AB, Rosland Nordic AB, Black T Quant AB and board member of Hunterhex International Inc, Hunterhex AB,  Evolutience Pharmaceutical AB,  Wonderboo AB, Emotra AB and Challengehop Inc.   

Independent in relation to the company and its management but not to major shareholders. 

Born in 1956. Board member since 2020.

Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuro-pharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.

Number of shares *): 125,202 shares and 213,331 shares through company
TO4 warrants: 46,950 and 79,998 warrants through company

Education: MSc in Chemistry, PhD in Medical Science, Adjunct Professor of Neuroscience at Uppsala University

Ongoing assignments: Board member of Dicot AB and Wissboda Gård AB.

Independent in relation to both the company and its management as well as to major shareholders.

Born in 1961. Board member since 2018.

Carol is an R&D and pharmaceutical development expert with more than 30 years of experience in UK and US-based pharmaceutical and biotechnology companies focusing on drug acquisition and profiling of NCE biology. She has played a key role in GSK Biopharmaceuticals, including management in pharmaceutical research and development activities in several therapeutic areas, especially in the areas of immuno-inflammatory diseases and neuroscience with an emphasis on translational medicine. She recently managed a semi-philanthropic dementia fund with a central focus on identifying and developing new disease-modified mechanisms for the treatment of all different types of dementia. She has over 90 articles published in scientific journals. Until recently Carol was the Director of Research and Managing Director of EDoN, a global early detection initiative at Alzheimer’s Research UK. She worked as Chief Medical and Scientific Officer at Small Pharma and is currently an independent biomedical consultant.

Number of shares: –

Education: BSc, in Biology/Zoology at Nottingham University, UK, and PhD in Neuroscience/Neuropharmacology at Queens Medical School, Nottingham, UK.

Ongoing assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Born in 1957. Board member since 2018.

Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development, financing and pharmaceutical development.

Number of shares: –

Education: DDS (Doctor of Dental Surgery) at University of Umeå

Ongoing assignments: Chairman of the of Mucolife Therapeutics AB.  Board member of Nexus BioSciences AB and, Anders Waas AB.

Independent in relation to both the company and its management and dependent of major shareholders.

Chief Executive Officer since 2024.

Tord brings over 15 years of extensive experience in senior leadership roles within the pharmaceutical industry. His expertise encompasses the entire pharmaceutical value chain, from initial discovery to regulatory approval and product launch.

Through his career Tord held various high-level positions at LEO Pharma, including Vice President & Head of Global Clinical Development, President and Japan Representative Director and Vice President of R&D Asia-Pacific.

Most recently,Tord worked as a senior consultant in the biotechnology, medical technology, and pharmaceutical sectors.

Tord’s diverse background in international pharmaceutical leadership, coupled with his experience across multiple therapeutic areas and global markets, positions him as a seasoned executive in the industry.

Shareholdings *): 153,600 shares
Warrants **): 1,000,000
TO4 warrants: 106,625

Education: M.Sci in Molecular Biology and a PhD in Immunology from Lund University

Other assignments: Board member of NanoEcho AB

Chief Scientific Officer since 2015.

Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on neurotoxic peptide devices.

Anders has since 2007 worked with the ALZ-101 and ALZ-201 projects as its main occupation, and as chief operating officer has run much of the Company’s operations since it was founded in 2011. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.

Shareholdings *): 149,437 shares
Warrants **): 500,000
TO4 warrants: 62,400

Education: PhD in biochemistry at University of Gothenburg, Sweden

Other assignments: –

Chief Financial Officer since 2024.

Erik has more than 25 years of experience within international finance and business administration in different sectors. His experience includes financial positions within Swedbank Robur, CFO and CEO at Dunross & Co AB, a privately owned investment company, and CEO at Reguity Group AB. Erik has also experience as interim Chief Financial Officer from several companies.

Shareholdings *): 250,000
Warrants **): 500,000
TO4 warrants: 110,000

Education: MSc in Business Administration from Gothenburg School of Business, Economics and Law at the University of Gothenburg

Other assignments: Chairman of the board of Spore Invest AB. Member of the board of RTI Group AB, Apprecia Foucault AB, NVR Kapitalförsäkring AB, Questor Advisory AB, Oak Bough Advisory AB and, Dunross & Co. foundation. Board alternate of AB Apprecia and MK Invest AB and, interim CFO of Stayble Therapeutics AB.

Vice President R&D Projects since 2021.

Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond.  Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies

Shareholdings *): 47,456 shares and 96,081 shares through company
Warrants **): 250,000
TO4 warrants: 17,796 and 36,030 warrants through company

Education: MSc Chemical Engineering, PhD Molecular Biology

Other assignments: CEO, ESP Life Science Consulting AB

Business Development Director since 2023.

Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.

Shareholdings *): 219,154 through companies
Warrants **): 250,000
TO4 warrants: 106,702 through companies

Education: MSc in Chemistry, PhD in Molecular Biophysics, MBA, Certified Board Member.

Other assignments: Board member of Bulb Intelligence AB, Tyto Competitive Intelligence Solutions AB and Scientific Intelligence Consulting Öresund AB.